Cargando…
Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study
BACKGROUND: In response to the recent serogroup W invasive meningococcal disease (IMD-W) epidemic in the Netherlands, meningococcal serogroup C (MenC) conjugate vaccination for children aged 14 months was replaced with a MenACWY conjugate vaccination, and a mass campaign targeting individuals aged 1...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258937/ https://www.ncbi.nlm.nih.gov/pubmed/34525199 http://dx.doi.org/10.1093/cid/ciab791 |
_version_ | 1784741661933305856 |
---|---|
author | Ohm, Milou Hahné, Susan J M van der Ende, Arie Sanders, Elisabeth A M Berbers, Guy A M Ruijs, Wilhelmina L M van Sorge, Nina M de Melker, Hester E Knol, Mirjam J |
author_facet | Ohm, Milou Hahné, Susan J M van der Ende, Arie Sanders, Elisabeth A M Berbers, Guy A M Ruijs, Wilhelmina L M van Sorge, Nina M de Melker, Hester E Knol, Mirjam J |
author_sort | Ohm, Milou |
collection | PubMed |
description | BACKGROUND: In response to the recent serogroup W invasive meningococcal disease (IMD-W) epidemic in the Netherlands, meningococcal serogroup C (MenC) conjugate vaccination for children aged 14 months was replaced with a MenACWY conjugate vaccination, and a mass campaign targeting individuals aged 14–18 years was executed. We investigated the impact of MenACWY vaccination implementation in 2018–2020 on incidence rates and estimated vaccine effectiveness (VE). METHODS: We extracted IMD cases diagnosed between July 2014 and December 2020 from the national surveillance system. We calculated age group–specific incidence rate ratios by comparing incidence rates before (July 2017–March 2018) and after (July 2019–March 2020) MenACWY vaccination implementation. We estimated VE in vaccine-eligible cases using the screening method. RESULTS: Overall, the IMD-W incidence rate declined by 61% (95% confidence interval [CI], 40 to 74). It declined by 82% (95% CI, 18 to 96) in the vaccine-eligible age group (individuals aged 15–36 months and 14–18 years) and by 57% (95% CI, 34 to 72) in vaccine-noneligible age groups. VE was 92% (95% CI, –20 to 99.5) in vaccine-eligible toddlers (aged 15–36 months). No IMD-W cases were reported in vaccine-eligible teenagers after the campaign. CONCLUSIONS: The MenACWY vaccination program was effective in preventing IMD-W in the target population. The IMD-W incidence reduction in vaccine-noneligible age groups may be caused by indirect effects of the vaccination program. However, disentangling natural fluctuation from vaccine effect was not possible. Our findings encourage the use of toddler and teenager MenACWY vaccination in national immunization programs. |
format | Online Article Text |
id | pubmed-9258937 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-92589372022-07-07 Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study Ohm, Milou Hahné, Susan J M van der Ende, Arie Sanders, Elisabeth A M Berbers, Guy A M Ruijs, Wilhelmina L M van Sorge, Nina M de Melker, Hester E Knol, Mirjam J Clin Infect Dis Major Articles and Commentaries BACKGROUND: In response to the recent serogroup W invasive meningococcal disease (IMD-W) epidemic in the Netherlands, meningococcal serogroup C (MenC) conjugate vaccination for children aged 14 months was replaced with a MenACWY conjugate vaccination, and a mass campaign targeting individuals aged 14–18 years was executed. We investigated the impact of MenACWY vaccination implementation in 2018–2020 on incidence rates and estimated vaccine effectiveness (VE). METHODS: We extracted IMD cases diagnosed between July 2014 and December 2020 from the national surveillance system. We calculated age group–specific incidence rate ratios by comparing incidence rates before (July 2017–March 2018) and after (July 2019–March 2020) MenACWY vaccination implementation. We estimated VE in vaccine-eligible cases using the screening method. RESULTS: Overall, the IMD-W incidence rate declined by 61% (95% confidence interval [CI], 40 to 74). It declined by 82% (95% CI, 18 to 96) in the vaccine-eligible age group (individuals aged 15–36 months and 14–18 years) and by 57% (95% CI, 34 to 72) in vaccine-noneligible age groups. VE was 92% (95% CI, –20 to 99.5) in vaccine-eligible toddlers (aged 15–36 months). No IMD-W cases were reported in vaccine-eligible teenagers after the campaign. CONCLUSIONS: The MenACWY vaccination program was effective in preventing IMD-W in the target population. The IMD-W incidence reduction in vaccine-noneligible age groups may be caused by indirect effects of the vaccination program. However, disentangling natural fluctuation from vaccine effect was not possible. Our findings encourage the use of toddler and teenager MenACWY vaccination in national immunization programs. Oxford University Press 2021-09-15 /pmc/articles/PMC9258937/ /pubmed/34525199 http://dx.doi.org/10.1093/cid/ciab791 Text en © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Articles and Commentaries Ohm, Milou Hahné, Susan J M van der Ende, Arie Sanders, Elisabeth A M Berbers, Guy A M Ruijs, Wilhelmina L M van Sorge, Nina M de Melker, Hester E Knol, Mirjam J Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study |
title | Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study |
title_full | Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study |
title_fullStr | Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study |
title_full_unstemmed | Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study |
title_short | Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study |
title_sort | vaccine impact and effectiveness of meningococcal serogroup acwy conjugate vaccine implementation in the netherlands: a nationwide surveillance study |
topic | Major Articles and Commentaries |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258937/ https://www.ncbi.nlm.nih.gov/pubmed/34525199 http://dx.doi.org/10.1093/cid/ciab791 |
work_keys_str_mv | AT ohmmilou vaccineimpactandeffectivenessofmeningococcalserogroupacwyconjugatevaccineimplementationinthenetherlandsanationwidesurveillancestudy AT hahnesusanjm vaccineimpactandeffectivenessofmeningococcalserogroupacwyconjugatevaccineimplementationinthenetherlandsanationwidesurveillancestudy AT vanderendearie vaccineimpactandeffectivenessofmeningococcalserogroupacwyconjugatevaccineimplementationinthenetherlandsanationwidesurveillancestudy AT sanderselisabetham vaccineimpactandeffectivenessofmeningococcalserogroupacwyconjugatevaccineimplementationinthenetherlandsanationwidesurveillancestudy AT berbersguyam vaccineimpactandeffectivenessofmeningococcalserogroupacwyconjugatevaccineimplementationinthenetherlandsanationwidesurveillancestudy AT ruijswilhelminalm vaccineimpactandeffectivenessofmeningococcalserogroupacwyconjugatevaccineimplementationinthenetherlandsanationwidesurveillancestudy AT vansorgeninam vaccineimpactandeffectivenessofmeningococcalserogroupacwyconjugatevaccineimplementationinthenetherlandsanationwidesurveillancestudy AT demelkerhestere vaccineimpactandeffectivenessofmeningococcalserogroupacwyconjugatevaccineimplementationinthenetherlandsanationwidesurveillancestudy AT knolmirjamj vaccineimpactandeffectivenessofmeningococcalserogroupacwyconjugatevaccineimplementationinthenetherlandsanationwidesurveillancestudy |